As RCCC are highly vascularises cancers, with high secretion of VEGF (Rioux-Leclercq et al, 2007), recent therapies are focused on anti-angiogenic drugs (Rini, 2009): anti-VEGF antibody (bevacizumab) (Rini et al, 2008) or tyrosine kinase inhibitors (Sunitinib, sorafenib) (Motzer et al, 2007; Negrier et al, 2009). This evidence concerns the gene VEGFA and cancer.